185 related articles for article (PubMed ID: 33871648)
1. Progressive Response to Repeat Application of Capsaicin 179 mg (8% w/w) Cutaneous Patch in Peripheral Neuropathic Pain: Comprehensive New Analysis and Clinical Implications.
Freynhagen R; Argoff C; Eerdekens M; Engelen S; Perrot S
Pain Med; 2021 Oct; 22(10):2324-2336. PubMed ID: 33871648
[TBL] [Abstract][Full Text] [Related]
2. Topical capsaicin (high concentration) for chronic neuropathic pain in adults.
Derry S; Sven-Rice A; Cole P; Tan T; Moore RA
Cochrane Database Syst Rev; 2013 Feb; (2):CD007393. PubMed ID: 23450576
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study.
Mankowski C; Poole CD; Ernault E; Thomas R; Berni E; Currie CJ; Treadwell C; Calvo JI; Plastira C; Zafeiropoulou E; Odeyemi I
BMC Neurol; 2017 Apr; 17(1):80. PubMed ID: 28431564
[TBL] [Abstract][Full Text] [Related]
4. 8% Capsaicin Patch in Treatment of Peripheral Neuropathic Pain.
Goncalves D; Rebelo V; Barbosa P; Gomes A
Pain Physician; 2020 Sep; 23(5):E541-E548. PubMed ID: 32967405
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients.
Hussain N; Said ASA; Javaid FA; Al Haddad AHI; Anwar M; Khan Z; Abu-Mellal A
J Diabetes Metab Disord; 2021 Jun; 20(1):271-278. PubMed ID: 34178837
[TBL] [Abstract][Full Text] [Related]
6. Treatment Impact on Patient-Reported Outcomes in Peripheral Neuropathic Pain: Comparing Single Intervention With Topical High-Concentration Capsaicin to Daily Oral Pregabalin.
Viel E; Eerdekens M; Kandaswamy P
Pain Physician; 2021 Sep; 24(6):453-463. PubMed ID: 34554688
[TBL] [Abstract][Full Text] [Related]
7. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study.
Maihofner C; Heskamp ML
Curr Med Res Opin; 2013 Jun; 29(6):673-83. PubMed ID: 23551064
[TBL] [Abstract][Full Text] [Related]
8. Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.
Perrot S; Lantéri-Minet M
Eur J Pain; 2019 Jul; 23(6):1117-1128. PubMed ID: 30793414
[TBL] [Abstract][Full Text] [Related]
9. Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice.
Hansson P; Jensen TS; Kvarstein G; Strömberg M
Eur J Pain; 2018 May; 22(5):941-950. PubMed ID: 29388284
[TBL] [Abstract][Full Text] [Related]
10. Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study.
Gálvez R; Navez ML; Moyle G; Maihöfner C; Stoker M; Ernault E; Nurmikko TJ; Attal N
Clin J Pain; 2017 Oct; 33(10):921-931. PubMed ID: 28872473
[TBL] [Abstract][Full Text] [Related]
11. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study.
Vinik AI; Perrot S; Vinik EJ; Pazdera L; Jacobs H; Stoker M; Long SK; Snijder RJ; van der Stoep M; Ortega E; Katz N
BMC Neurol; 2016 Dec; 16(1):251. PubMed ID: 27919222
[TBL] [Abstract][Full Text] [Related]
12. Treatment of painful radiculopathies with capsaicin 8% cutaneous patch.
Baron R; Treede RD; Birklein F; Cegla T; Freynhagen R; Heskamp ML; Kern KU; Maier C; Rolke R; Seddigh S; Sommer C; Ständer S; Maihöfner C
Curr Med Res Opin; 2017 Aug; 33(8):1401-1411. PubMed ID: 28436279
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in Peripheral Neuropathic Pain: Multi-Center, Randomized, and Semi-Double Blind Controlled Study.
Moon JY; Lee PB; Kim YC; Lee SC; Nahm FS; Choi E
Pain Physician; 2017 Feb; 20(2):27-35. PubMed ID: 28158151
[TBL] [Abstract][Full Text] [Related]
14. Is the Capsaicin 179 mg (8% w/w) Cutaneous Patch an Appropriate Treatment Option for Older Patients with Peripheral Neuropathic Pain?
Pickering G; Engelen S; Stupar M; Ganry H; Eerdekens M
J Pain Res; 2024; 17():1327-1344. PubMed ID: 38560405
[TBL] [Abstract][Full Text] [Related]
15. The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis.
Wagner T; Poole C; Roth-Daniek A
Pain Med; 2013 Aug; 14(8):1202-11. PubMed ID: 23710678
[TBL] [Abstract][Full Text] [Related]
16. QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France.
Lantéri-Minet M; Perrot S
Curr Med Res Opin; 2019 Mar; 35(3):417-426. PubMed ID: 30550354
[TBL] [Abstract][Full Text] [Related]
17. Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study.
Simpson DM; Robinson-Papp J; Van J; Stoker M; Jacobs H; Snijder RJ; Schregardus DS; Long SK; Lambourg B; Katz N
J Pain; 2017 Jan; 18(1):42-53. PubMed ID: 27746370
[TBL] [Abstract][Full Text] [Related]
18. Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain.
Blair HA
Drugs; 2018 Sep; 78(14):1489-1500. PubMed ID: 30251173
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Impact of Capsaicin 8% Patch on Quality of Life in Patients with Lumbosacral Pain: An Open-label Study.
Zis P; Bernali N; Argira E; Siafaka I; Vadalouka A
Pain Physician; 2016; 19(7):E1049-53. PubMed ID: 27676676
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and outcomes of peripheral neuropathic pain patients with repeated applications of high-concentration capsaicin cutaneous patch: Results of a retrospective chart review in Germany.
Kern KU; Quandel T; Theis S; Schubert T
Pain Pract; 2024 Jun; 24(5):700-708. PubMed ID: 38321913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
